• Wondering if Solventum at around US$67.51 is offering value or just noise in the healthcare space? This article walks you through what the current price could mean for you.
• Over the short term, Solventum has seen a 2.1% decline over the last 7 days, a 7.6% return over 30 days, and a 14.6% decline year to date, while the 1 year return sits at 1.9%.
• Recent coverage of Solventum has focused on its position in the Medical Equipment industry and how investors are reacting to its standalone listing from 3M. Commentary has also highlighted investor interest in how Solventum plans to operate as an independent healthcare company and what that could mean for future capital allocation.
• Right now, Solventum scores 4 out of 6 on Simply Wall St's valuation checks, giving it a 4/6 valuation score. The next sections will walk through the different valuation methods behind that score, before finishing with a way to look at valuation that goes beyond the usual numbers.

Approach 1: Solventum Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and then discounting them back to today’s value using a required rate of return.

For Solventum, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in $. The latest twelve month free cash flow is reported at $16.52 million. Analyst projections and subsequent extrapolations by Simply Wall St extend out to 2035, with forecast free cash flow for 2029 of $944 million, and discounted values provided for each year in between.

Pulling those projected cash flows together, the DCF model arrives at an estimated intrinsic value of US$82.29 per share. Compared with the current share price of around US$67.51, this implies an intrinsic discount of about 18.0%. This suggests the shares are trading below this model’s estimate of fair value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Solventum is undervalued by 18.0%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Solventum Price vs Earnings

For a profitable business, the P/E ratio is a useful yardstick because it links what you pay directly to the earnings the company is already generating. Investors usually accept a higher or lower P/E depending on what they expect for future growth and how risky they feel those earnings are. Higher growth or lower perceived risk can justify a higher “normal” P/E, while slower growth or higher risk can point to a lower one.

Solventum currently trades on a P/E of 7.5x. That sits well below the Medical Equipment industry average P/E of about 24.0x and also below the peer group average of 29.0x. On the surface, that gap suggests the market is putting a lower value on Solventum’s earnings than on those of its sector and peer companies.

Simply Wall St’s Fair Ratio for Solventum is 20.4x. This is a proprietary estimate of what the P/E might be, given factors such as the company’s earnings growth profile, industry, profit margin, market cap and specific risks. Because it brings all of these into one number, the Fair Ratio can give a more tailored view than simple comparisons with peers or an industry average. Set against the current 7.5x P/E, the Fair Ratio points to Solventum trading below this model’s estimate of a more typical earnings multiple.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Solventum Narrative

Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a simple story that links your view of Solventum to a financial forecast and then to a personal fair value.

On Simply Wall St’s Community page, a Narrative lets you spell out why you think Solventum develops as it does, then tie that story to your own assumptions for future revenue, earnings and margins so you can see a fair value that matches your view.

Because Narratives constantly compare that fair value with the current price, they help you consider whether Solventum appears closer to your own buy, hold or sell zone, and they update automatically when fresh news or earnings data is added.

For example, one investor might build a bullish Solventum Narrative around earnings of about US$3.2b and a fair value near US$105.00. Another might build a more cautious Narrative around earnings closer to US$315.3m and a fair value near US$71.00, with both views sitting side by side so you can see where your own expectations fit.

Do you think there's more to the story for Solventum? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.